Purdue Appeals Par's Defeat Of Ultram Patents

Law360, New York (September 3, 2009, 7:14 PM EDT) -- With its control over Ultram ER in peril, Purdue Pharma Products LP has appealed a federal judge's August decision that invalidated Purdue’s patents for the painkiller and cleared the way for Par Pharmaceuticals Inc. to market a generic version of the drug.

On Thursday, Purdue and Napp Pharmaceutical Group Ltd. lodged an appeal with the U.S. Court of Appeals for the Federal Circuit, challenging the district court’s declaration that the two Ultram patents are invalid for obviousness.

On Aug.14, Judge Kent A. Jordan of the U.S....
To view the full article, register now.